Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
A comprehensive subgroup analysis of the CATIS and CATIS-2 trials reveals that continuing or reinitiating antihypertensive medication immediately after an acute ischemic stroke does not significantly affect mortality or disability rates, pr
A randomized controlled trial demonstrates that 6-month atorvastatin treatment significantly reduces aneurysm wall enhancement and systemic inflammatory markers in patients with unruptured vertebrobasilar dissecting aneurysms, potentially o
A secondary analysis of the PRESTIGE-AF trial reveals that specific MRI markers, including cortical superficial siderosis and macrohemorrhages, are more potent predictors of recurrent intracerebral hemorrhage than hematoma location alone, o
The Phase II HiWalk trial demonstrates that a 43-hour high-intensity walking booster program is safe and feasible for chronic stroke survivors, yielding significant walking speed improvements for individuals who have already completed their
The TaCAS long-term follow-up study reveals that a simple, conversation-based intervention can sustain improvements in physical health and independence for up to six years post-stroke, highlighting the lasting impact of patient-centered mot
A multicenter randomized controlled trial demonstrates that drug-coated balloons significantly reduce 6-month restenosis and 1-year recurrent ischemic events compared to bare-metal stents in patients with symptomatic high-grade intracranial
A multicenter RCT demonstrates that drug-coated balloon (DCB) angioplasty significantly reduces 6-month restenosis and 1-year recurrent ischemic events compared to bare-metal stenting in patients with high-grade symptomatic intracranial ath
The multicenter TASTE-2 trial reveals that edaravone dexborneol significantly increases the likelihood of functional independence at 90 days for acute ischaemic stroke patients undergoing thrombectomy, particularly those presenting with a c
A sub-analysis of the FINGER trial reveals that individuals with specific grey matter patterns and lower vascular risk derive the most structural brain benefit from multimodal lifestyle interventions, highlighting the potential for personal
The ANGEL-REBOOT trial reveals that while bailout angioplasty (BAOS) increases short-term procedural risks, it significantly improves one-year functional outcomes and reduces stroke recurrence in patients with failed thrombectomy or high-gr
The landmark BHF PROTECT-TAVI trial reveals that cerebral embolic protection (CEP) does not reduce periprocedural stroke or cognitive impairment following TAVI. This large-scale study challenges the routine use of embolic filters, suggestin
A multicenter randomized trial confirms that a novel biodegradable PFO closure device is noninferior to nitinol devices, achieving high closure rates and disappearing from echocardiography within two years, potentially reducing long-term fo
A long-term analysis of the FOURIER trials reveals that achieving ultra-low LDL-C levels (<40 mg/dL) significantly reduces recurrent stroke and major cardiovascular events in stroke survivors, without increasing hemorrhagic stroke risk,
While the primary i-DEF trial results suggested futility for deferoxamine in unselected intracerebral hemorrhage patients, recent post hoc analyses reveal significant benefits in early neurological improvement, long-term recovery trajectori
A post hoc analysis of the SWITCH trial demonstrates that the clinical benefits of decompressive craniectomy in reducing death and severe disability are consistent across different anatomical locations of deep supratentorial intracerebral h
The C-GUARDIANS trial reveals that the CGuard MicroNet-covered stent significantly reduces embolic risks in high-risk carotid artery stenting, achieving a remarkably low 30-day DSMI rate of 0.95% and sustained neuroprotection through one ye
The RESOLVE trial demonstrates that graded sensorimotor retraining provides modest pain relief for chronic low back pain. A secondary analysis reveals that these benefits are consistent across most patient subgroups, suggesting that the int
A pivotal Phase 3 study published in NEJM demonstrates that Fremanezumab significantly reduces monthly migraine days in children and adolescents, offering a targeted, evidence-based preventive option for a population with high unmet medical
Highlights Background Dementia and depression are intertwined public health crises, together accounting for a substantial…
A large-scale study of 144,969 Medicare beneficiaries reveals that initial anticoagulant prescriptions for atrial fibrillation may not reduce ischemic stroke risk in patients over 66, while significantly increasing major bleeding hazards, s
Open language-specific specialty feeds and department pages.